Abstract

Preclinical studies have revealed that the elevation of nicotinamide adenine dinucleotide (NAD + ) upon the administration of nicotinamide mononucleotide (NMN), an NAD + precursor, can mitigate aging-related disorders; however, human data on this are limited. We investigated whether the chronic oral supplementation of NMN can elevate blood NAD + levels and alter physiological dysfunctions in healthy older participants. We administered 250 mg NMN per day to aged men for 6 or 12 weeks in a placebo-controlled, randomized, double-blind, parallel-group trial. Chronic NMN supplementation was well tolerated and caused no significant deleterious effect. Metabolomic analysis of whole blood samples demonstrated that oral NMN supplementation significantly increased the NAD + and NAD + metabolite concentrations. There were nominally significant improvements in gait speed and performance in the left grip test, which should be validated in larger studies; however, NMN exerted no significant effect on body composition. Therefore, chronic oral NMN supplementation can be an efficient NAD + booster for preventing aging-related muscle dysfunctions in humans.

Details

Title
Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men
Author
Igarashi Masaki 1   VIAFID ORCID Logo  ; Nakagawa-Nagahama Yoshiko 1   VIAFID ORCID Logo  ; Miura Masaomi 1 ; Kashiwabara Kosuke 2 ; Yaku Keisuke 3 ; Sawada Mika 4 ; Sekine Rie 4 ; Fukamizu Yuichiro 5   VIAFID ORCID Logo  ; Sato Toshiya 5 ; Sakurai Takanobu 5 ; Sato Jiro 6 ; Ino Kenji 7 ; Kubota Naoto 8 ; Nakagawa, Takashi 3   VIAFID ORCID Logo  ; Kadowaki Takashi 9 ; Yamauchi Toshimasa 1 

 The University of Tokyo, Department of Diabetes & Metabolic Diseases, Graduate School of Medicine, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X) 
 The University of Tokyo Hospital, Data Science Office, Clinical Research Promotion Center, Tokyo, Japan (GRID:grid.412708.8) (ISNI:0000 0004 1764 7572) 
 University of Toyama, Department of Molecular and Medical Pharmacology, Faculty of Medicine, Toyama, Japan (GRID:grid.267346.2) (ISNI:0000 0001 2171 836X) 
 The University of Tokyo Hospital, The University of Tokyo, Department of Clinical Nutrition Therapy, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X) 
 Mitsubishi Corporation Life Sciences Limited, Tokyo, Japan (GRID:grid.465204.1) (ISNI:0000 0001 2284 8174) 
 Department of Radiology, Tokyo Metropolitan Police Hospital Tokyo, Tokyo, Japan (GRID:grid.417117.5) (ISNI:0000 0004 1772 2755) 
 The University of Tokyo Hospital, Department of Radiation Technology, Tokyo, Japan (GRID:grid.412708.8) (ISNI:0000 0004 1764 7572) 
 The University of Tokyo, Department of Diabetes & Metabolic Diseases, Graduate School of Medicine, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X); The University of Tokyo Hospital, The University of Tokyo, Department of Clinical Nutrition Therapy, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X) 
 Toranomon Hospital, Tokyo, Japan (GRID:grid.410813.f) (ISNI:0000 0004 1764 6940) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20563973
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2658034831
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.